Combination therapy with apilimod and glutamatergic agents

1. A method for treating a neurological disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, in combination with an antioxidant.

2. The method of claim 1 , wherein the apilimod is apilimod dimesylate.

3. The method of claim 2 , wherein the antioxidant is edaravone.

4. The method of claim 3 , wherein the apilimod and the antioxidant are administered as part of a therapeutic regimen comprising administration of a glutamatergic agent.

5. The method of claim 4 , wherein the glutamatergic agent is selected from a glutamate transporter modulating agent and a glutamate receptor antagonist.

6. The method of claim 5 , wherein the glutamatergic agent is a glutamate transporter modulating agent selected from an excitatory amino acid reuptake inhibitor.

7. The method of claim 5 , wherein the glutamatergic agent is a glutamate receptor antagonist selected from an N-methyl-D-aspartate (NMDA) receptor antagonist.

8. The method of claim 5 , wherein the glutamatergic agent is a glutamate receptor antagonist selected from the group consisting of AP5 (R-2-amino-5-phosphonopentanoate), AP7 (2-amino-7-phosphonoheptanoic acid), CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), CPPene (3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1-phosphonic acid), NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione), and selfotel (CGS-19755).

9. The method of claim 5 , wherein the glutamatergic agent is a glutamate receptor antagonist selected from the group consisting of amantadine, atomoxetine, AZD6765, agmatine, gacyclidine, ketamine, memantine, eliprodil, delucemin.

10. The method of claim 5 , wherein the glutamatergic agent is selected from BHV-5000, lamotrigine, lanicemine, riluzole, trigriluzole, and topiramate.

11. The method of claim 10 , wherein the glutamatergic agent is riluzole or trigriluzole.

12. The method of claim 1 , wherein the pharmaceutical composition is an oral dosage form or a sublingual dosage form.

13. The method of claim 1 , wherein the antioxidant is administered in the same or a different dosage form as the apilimod.

14. The method of claim 1 , wherein the neurological disease or disorder is selected from Alzheimer's disease, amyotrophic lateral sclerosis (ALS), attention deficit hyperactivity disorder, autism, cerebellar ataxia, Charcot-Marie-Tooth disease, Creutzfeldt-Jakob disease, dementia, epilepsy, Friedreich's ataxia, Huntington's disease, multiple sclerosis, obsessive compulsive disorder (OCD), Parkinson's disease, Rett syndrome, senile chorea, spinal ataxia, spinal cord injury, supranuclear palsy, traumatic brain injury.

15. The method of claim 14 , wherein the neurological disease or disorder is dementia.

16. The method of claim 15 , wherein the dementia is selected from AIDS dementia complex (ADC), dementia associated with Alzheimer's disease (AD), dementia pugilistica, diffuse Lewy body disease, frontotemporal dementia, mixed dementia, senile dementia of Lewy body type, and vascular dementia.

17. The method of claim 14 , wherein the neurological disease or disorder is amyotrophic lateral sclerosis (ALS).

18. The method of claim 1 , wherein the subject is human.

19. A method for treating amyotrophic lateral sclerosis (ALS) in a human subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, in combination with edaravone.

20. The method of claim 19 , further comprising administering to the subject a glutamatergic agent selected from riluzole or trigriluzole.

21. The method of claim 19 , wherein the apilimod is apilimod dimesylate.